Information Provided By: 
Fly News Breaks for January 17, 2019
FOLD
Jan 17, 2019 | 07:37 EDT
Citi analyst Mohit Bansal last night upgraded Amicus Therapeutics to Buy from Neutral with a $16 price target. In recent months, the expectations on accelerated approval for AT-GAA have come down, Bansal tells investors in a research note. Further, he feels more confident on pivotal trial timelines as the company has opened 90 sites for enrollment. He sees value in owning Amicus shares in 2019.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
